Completed PHASE1 INTERVENTIONAL NCT00004178

Gene Therapy in Treating Patients With Cancer

Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma

Sponsor: Beth Israel Deaconess Medical Center

Conditions Cancer

Interventions therapeutic autologous lymphocytes

Updated 5 times since 2017 Last updated: Jun 9, 2011 Started: Apr 30, 1998 Primary completion: Dec 31, 2000 Completion: Dec 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004178, this PHASE1 trial focuses on Cancer and remains completed. Sponsored by Beth Israel Deaconess Medical Center, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Deaconess Medical Center
Roger Williams Medical Center

Data source: Roger Williams Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States